Find Funding Opportunities

 COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements

All NINDS-related notices of funding opportunities (NOFOs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Opportunities tab to find expired opportunities. Search the Notices tab to find all Notices.

Learn more about award types and program directors and managers.

NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!

For more focused results add quotes to indicate parameters. Example format: "search term".

Expiration Date: Saturday, September 27, 2025 NOFO Number: PAR-23-178 Release Date: Monday, June 12, 2023 Notice Type: PAR
This NIH Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25) is a flexible and specialized program designed to foster the development of neuroscience researchers from diverse backgrounds, including from underrepresented groups across career stages. Thus, it encourages applications from applicant organizations that propose innovative mentoring and professional development activities in the mission area(s) of the NINDS and/or NIMH. This Neuroscience Diversity R25 initiative will focus on factors that have been shown to affect retention of underrepresented graduate students, postdoctoral trainees, and junior faculty in neuroscience research such as mentoring, scientific networks, professional development, and attention to the structural and institutional environment regarding inclusion (; Structure and Belonging: Pathways to Success for Underrepresented Minority and Women Ph.D. Students in STEM Fields; The Science of Effective Mentorship in STEMM).The NIH expects applicant institutions to propose programs that will lead to an improvement in the professional development, mentoring and technical expertise of individuals who are individuals from diverse backgrounds, including those from groups that are nationally underrepresented in neuroscience research. Programs that target transitions and/or more than one career stage for neuroscience career advancement and progression are strongly encouraged. This initiative will support the development of collaborative research education partnerships that will increase participants awareness and interest in the neurosciences, develop participants scientific knowledge and research skills that will allow them to progress and transition to more advanced neuroscience-related research education and training activities. Proposed program interventions to enhance workforce diversity in response to this FOA should also focus on asset models and leadership opportunities, rat
Research Category: HEAL Initiative, Pain Expiration Date: Tuesday, October 3, 2023 NOFO Number: RFA-AT-24-003 Release Date: Thursday, June 8, 2023 Notice Type: RFA

The National Institutes of Health (NIH) intends to support the development of innovative methods for quantitative evaluation of myofascial tissues for pain management involving research participants using a two-phase grant funding mechanism. This effort is part of the NIH HEALSM (Helping to End Addiction Long-term) Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is bolstering research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management. This notice of funding opportunity (NOFO) seeks research applications to develop quantitative measures of myofascial tissues and assess their abilities to detect changes to myofascial tissues across a variety of pain management interventions. Candidate objective measures may be based on minimally invasive imaging technologies, electrophysiological recordings, integration of multiparametric imaging and electrophysiology approaches, or their integration with other markers (e.g., immune factors, genomic markers, physiological factors) through multiscale modeling or machine learning analysis. The first phase, funded by the R61, will provide funding for up to 3 years to develop quantitative measures that can differentiate abnormal myofascial tissue from healthy tissues using cross-sectional correlations with clinical signs/symptoms. In addition, the R61 phase should include planning activities for the R33 phase. The second phase, funded under the R33, will provide support to assess the abilities of the quantitative measures developed in the R61 phase to measure tissue changes in response to therapies or manipulations that may relieve pain using rigorous, longitudinal clinical study design. The combined R61/R33 should not exceed 5 years. Transition from the R61 to the R33 phase of the award will be administratively reviewed and will be determined based on successful co

Expiration Date: Monday, May 26, 2025 NOFO Number: PAR-23-199 Release Date: Tuesday, June 6, 2023 Notice Type: PAR
NIH established a clinical genomics infrastructure to develop an openly accessible knowledgebase that promotes data sharing and provides standardized infrastructure and tools for determining the clinical relevance of genetic variants through two initiatives: the Clinical Genomics Resource (ClinGen) and the Clinical Variant Database (ClinVar) of clinical variation. ClinGen defines the clinical relevance of genes and variants for use in precision medicine and research by standardizing clinical annotation and interpretation of variants and implementing evidence-based expert consensus assertions. The purpose of this Notice of Funding Opportunity (NOFO) is to establish Expert Panels that will select genes and genomic variants associated with diseases or conditions of high priority to participating NIH Institutes and Centers (ICs) and systematically determine their clinical significance for diagnosis and treatment of these diseases or conditions. The Genomic Curation Expert Panels funded through this NOFO are required to utilize the NHGRI Clinical Genomics Resource (ClinGen) and the NCBI ClinVar procedures, interfaces, tools, and informatics infrastructure.
Expiration Date: Thursday, October 5, 2023 NOFO Number: PAR-23-214 Release Date: Tuesday, June 6, 2023 Notice Type: PAR
"This FOA will solicit R01 applications that propose studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which COVID-19 interacts with and/or modulates AD/ADRD-relevant phenotypes. Either the model itself or the experimental readouts will be required to incorporate AD/ADRD risk factors, pathologies, or relevant comorbidities. To this end, proposals can focus on one or more of the following: - Mechanistic studies that address how COVID-19 impacts CNS pathology and cognitive outcomes when AD/ADRD pathology is already present (for example, in a model of AD/ADRD). - Mechanistic studies that address how COVID-19 accelerates AD/ADRD pathology and cognitive deficits in a prodromal model (early phase, pre-symptomatic). - Mechanistic studies that address how COVID-19 predisposes for AD/ADRD and/or interacts with relevant comorbid conditions and risk factors (cellular mechanisms that could potentially increase the risk for future AD/ADRD)."
Expiration Date: Saturday, August 8, 2026 NOFO Number: PAR-23-166 Release Date: Friday, June 2, 2023 Notice Type: PAR
The purpose of theNative American Research Centers for Health (NARCH) program is to fund federally-recognized American Indian/Alaska Native (AI/AN) tribes and tribal organizations to support health-related research, research career enhancement, and research infrastructure enhancement activities.
Expiration Date: Thursday, July 9, 2026 NOFO Number: PAR-23-184 Release Date: Friday, May 26, 2023 Notice Type: PAR
The Center for Inherited Disease Research (CIDR) high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes or genetic modifications that contribute to human health and disease or to enhance existing collections of well-phenotyped specimens in biorepositories by the addition of genotype or next-generation sequence data. The laboratory specializes in genomic services that cannot be efficiently carried out in individual investigator laboratories. CIDR provides the most up-to-date platforms, services and statistical genetic support. This is an NIH-wide initiative that is managed by NHGRI. Information about current services offered can be accessed via:
Expiration Date: Thursday, October 5, 2023 NOFO Number: PAR-23-212 Release Date: Tuesday, May 23, 2023 Notice Type: PAR
This FOA would support establishing deeper mechanistic insight and causal relationships between TDP-43 pathology and phenotypic outcomes, as well as mechanistic interactions between TDP-43 and other co-pathologies, such TMEM106B. Additionally, it would include comparisons (including mechanistic, molecular, structural, cellular, genetic, -omic, anatomical, neuropathological, etc.) between TDP-43 proteinopathies, including LATE, with or without AD-NC, and FTD and/or ALS.
Expiration Date: Thursday, October 5, 2023 NOFO Number: PAR-23-211 Release Date: Tuesday, May 23, 2023 Notice Type: PAR
This FOA would support investigations with a minimum of two relevant co-pathologies (e.g., tau, alpha-synuclein, TDP-43, TMEM106B, vascular), with optional risk factors and co-morbidities, to identify cellular and molecular mechanisms of how/why multi-proteinopathy interactions drive worsening neurodegenerative processes and phenotypic outcomes. Studies should examine co-pathology cellular and molecular interactions across brain regions and time in proximate cell population, across various intracellular dynamics and localization, and upstream and downstream from aggregated protein states to determine what events lead to worse phenotypic outcomes.
Expiration Date: Wednesday, October 9, 2024 NOFO Number: RFA-NS-23-027 Release Date: Monday, May 15, 2023 Notice Type: RFA
Reissue of RFA-NS-22-011 to comply with DMSP changes. No changes to receipt dates or locus of review. This funding opportunity announcement (FOA) is designed to support integrated efforts of three or more (up to six) PDs/PIs to pursue bold, impactful, and challenging research in any area within the scope of the NINDS mission. The research approach should be interdisciplinary in nature, and the research teams are expected to establish a common goal that requires collaboration, synergy, and managed team interactions. Proposed research should not represent a collection of individual efforts or parallel projects. This program is distinct from the NINDS P01 in that it will support a cohesive, single, well-integrated research plan with a singular focus, one set of aims, and a budget without subprojects. Teams are encouraged to consider transformative objectives with defined 5-year outcomes.
Research Category: HEAL Initiative, Pain Expiration Date: Wednesday, September 27, 2023 NOFO Number: RFA-NS-24-015 Release Date: Tuesday, May 9, 2023 Notice Type: RFA

This concept would support the development of pain clinical trainees as a means of enhancing the clinical pain workforce. It would fund 4 clinical pain T90/R90s that would provide robust post-doctoral fellowship research training in areas of clinical pain management that would benefit from further research. The T90/R90 mechanism is a NRSA program that supports comprehensive interdisciplinary research training programs at the undergraduate, predoctoral, and/or post-doctoral levels by capitalizing on the infrastructure of existing multidisciplinary and interdisciplinary research programs. The HEAL T90/R90 program would focus on training post-doctoral fellows with T90 trainees being those who are NRSA eligible and R90 trainees (maximum of 1 per award per year) being those who do not meet qualifications for NRSA support (including non-US citizens or residents). Trainees would either need to have a clinical degree or have a non-clinical degree but are interested in conducting clinical pain research. The T90/R90 training programs would provide mentoring and training to promote the successful transition of the trainees to independent research careers in academic or government settings. Unlike the T32 mechanism, the T90/R90 mechanism would support the dedication of 10% of the programs mentors time to mentoring the next generation of clinical pain researchers. The newly funded T90/R90s would work in coordination with the HEAL R24 Coordinating Center to ensure that trainees participate in the network, collaborative events/webinars, build relationships with basic and clinical science trainees, and attend the annual workshop. The NIH will prioritize funding T90/R90s universities and institutions that do not currently have a pain T32 or have not previously received funding for a pain T32. T90/R90 applicants are encouraged to partner with another university or institution to help increase the interdisciplinary nature of the mentors and trainees.

Export to:
A maximum of 400 records can be exported.